Cargando…
The CYTO-PV: A Large-Scale Trial Testing the Intensity of CYTOreductive Therapy to Prevent Cardiovascular Events in Patients with Polycythemia Vera
Polycythemia vera (PV) is a chronic myeloproliferative disorder whose major morbidity and mortality are thrombohaemorragic events. Current guidelines advise maintaining hematocrit (HCT) level below 45% in males and 42% in females. Such targets lean on pathophysiological reasoning, while evidence fro...
Autores principales: | Marchioli, Roberto, Finazzi, Guido, Specchia, Giorgina, Masciulli, Arianna, Mennitto, Maria Rosaria, Barbui, Tiziano |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3200258/ https://www.ncbi.nlm.nih.gov/pubmed/22084668 http://dx.doi.org/10.1155/2011/794240 |
Ejemplares similares
-
Different effect of hydroxyurea and phlebotomy on prevention of arterial and venous thrombosis in Polycythemia Vera
por: Barbui, Tiziano, et al.
Publicado: (2018) -
Clinical outcomes under hydroxyurea treatment in polycythemia vera: a systematic review and meta-analysis
por: Ferrari, Alberto, et al.
Publicado: (2019) -
Incidence of solid tumors in polycythemia vera treated with phlebotomy with or without hydroxyurea: ECLAP follow-up data
por: Ghirardi, Arianna, et al.
Publicado: (2018) -
Neutrophil-to-lymphocyte ratio is a novel predictor of venous thrombosis in polycythemia vera
por: Carobbio, Alessandra, et al.
Publicado: (2022) -
Polycythemia vera treatment algorithm 2018
por: Tefferi, Ayalew, et al.
Publicado: (2018)